Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Sales of diabetes-obesity drug Mounjaro could play a big role at Lilly in future years. Photo: Sandy Huffaker for The Washington Post/Getty Images Eli Lilly LLY 0.18 % increase; green up pointing ...

Eli Lilly (LLY) is following the right approach for the obesity drugs business as it explores multiple ways to address the balance between demand and supply, according to Truist Securities. The ...

Novo Nordisk, Eli Lilly poised to divvy up obesity market that could be worth $50B in 2030: analysts. By Fraiser Kansteiner Jul 15, 2022 11:20am. Novo Nordisk Eli Lilly Wegovy Ozempic ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

Eli Lilly LLY0.22%increase; green up pointing triangle is surging ahead in the race to dominate the lucrative obesity market. That is the takeaway from the disappointing Novo Nordisk NOVO.B 0.98 ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday. The drug will ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor.Clinical trial results from competitors were largely underwhelming, including this week’s ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Summary. Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion ...